Xuanzhu Biopharmaceutical Co., Ltd. 軒竹生物科技股份有限公司 (a joint stock company incorporated in the People's Republic of China with limited liability) （一家於中華人民共和國註冊成立的股份有限公司） (Stock code 股份代號: 2575) 21 November 2025 Dear registered shareholder(s), Arrangement of Electronic Dissemination of Corporate Communications Pursuant to Rule 2.07 of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic disse ...

Core Viewpoint - The company, Xuan Zhu Biological-B (02575), has submitted a filing application to the China Securities Regulatory Commission (CSRC) for the proposed implementation of full circulation of H-shares, converting a total of 357,245,794 unlisted shares into H-shares on a one-to-one basis [1] Group 1 - The company plans to convert 357,245,794 unlisted shares into H-shares, which will then be listed and traded on the Hong Kong Stock Exchange [1] - The conversion is subject to the completion of all filing requirements, including approval from the CSRC and the Hong Kong Stock Exchange [1] - The company aims to comply with all applicable laws, regulations, and rules during this process [1]

Core Viewpoint - Xuan Zhu Bio-B (02575) has submitted a filing application to the China Securities Regulatory Commission (CSRC) for the proposed implementation of full circulation of H-shares, converting a total of 357,245,794 unlisted shares into H-shares on a one-to-one basis [1] Group 1 - The company plans to convert 357,245,794 unlisted shares into H-shares, which will then be listed and traded on the Stock Exchange of Hong Kong [1] - The conversion is subject to the completion of all filing requirements, including approval from the CSRC and the Stock Exchange of Hong Kong [1] - The company aims to comply with all applicable laws, regulations, and rules during this process [1]

Core Viewpoint - Xuan Zhu Bio-B (02575.HK) has submitted a filing to the China Securities Regulatory Commission (CSRC) for the proposed implementation of full circulation of H-shares, converting approximately 357 million unlisted shares into H-shares on a one-to-one basis [1] Group 1 - The company plans to convert approximately 357 million unlisted shares into H-shares, which will then be listed and traded on the Hong Kong Stock Exchange [1] - The conversion is subject to the completion of all filing requirements, including obtaining necessary approvals from the CSRC and the Stock Exchange [1] - The proposed conversion aims to enhance liquidity and marketability of the company's shares [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Xuanzhu Biopharmaceutical Co., Ltd. 軒竹生物科技股份有限公司 （一家於中華人民共和國註冊成立的股份有限公司） （股份代號：2575） 內幕消息 本公司就建議實施H股全流通向中國證監會備案 董 事 會 欣 然 宣 佈，於 二 零 二 五 年 十 一 月 十 七 日，本 公 司 已 向 中 國 證 監 會 提 交 備 案 申 請，內 容 有 關 建 議 實 施H股 全 流 通，以 按 一 對 一 基 準 將 合 共357,245,794股 未上市股份轉換為H股。待 完 成 所 有 備 案 規 定（包 括 向 中 國 證 監 會 備 案）並 獲 得 所 有 相 關 批 准（包 括 聯 交 所 批 准 轉 換 及 上 市）並 遵 守 所 有 適 用 法 律、法 規 及 規 則 後，357,245,794股未上市股份將轉換 ...

Core Viewpoint - The company has announced a proposal for full circulation of H-shares, converting 357,245,794 unlisted shares held by six shareholders into H-shares, which represents approximately 68.9733% of the total issued shares as of the announcement date [1] Group 1 - The board of directors approved the implementation of the H-share full circulation proposal on November 14, 2025 [1] - The conversion of unlisted shares into H-shares is subject to obtaining all necessary approvals, including filing with the China Securities Regulatory Commission [1] - The company plans to apply for the listing and trading of these H-shares on the main board of the Stock Exchange of Hong Kong [1]

Core Viewpoint - The company, Xuan Zhu Biological-B (02575.HK), announced the implementation of a full circulation of H-shares, converting approximately 357 million unlisted shares held by six shareholders into H-shares, which represents about 68.9733% of the total issued shares as of the announcement date [1] Group 1 - The board of directors approved the proposal for H-share full circulation [1] - The conversion involves approximately 357 million shares [1] - The converted shares account for about 68.9733% of the total issued shares [1]

軒竹生物科技股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Xuanzhu Biopharmaceutical Co., Ltd. 於 本 公 告 日 期，本 公 司 尚 未 向 中 國 證 監 會 申 請H股 全 流 通。本 公 司 轉 換 及 上 市 實 施 計 劃 的 詳 情 尚 未 落 實，將 予 轉 換 的 未 上 市 股 份 最 終 數 目 以 及 轉 換 及 上 市 的 完 成 須 待 中 國 證 監 會、聯 交 所 及 其 他 相 關 國 內 外 監 管 機 構 規 定 的 相 關 程 序 履 行 後 方 可 作 實。本 公 司 將 根 據 上 市 規 則 及╱或 內 幕 消 息 條 文 於 適 當 時 候 就H 股 全 流 通 以 及 轉 換 及 上 市 的 進 展 作 出 進 一 步 公 告。 （一家於中華人民共和國註冊成立的股份有限公司） （股份代號：2575 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 軒竹生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司, 「本公司」） 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02575 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 160,701,996 | RMB | | 1 RMB | | 160,701,996 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 160,701,996 | RMB | | 1 RMB | | 160,701,996 | | 2 ...

Group 1 - XuanZhu Bio-B (02575) saw a significant increase in stock price, rising over 9% to reach a new high of 71.6 HKD, with a current price of 69.7 HKD and a trading volume of 38.59 million HKD [1] - The company announced that its product NG-350A, licensed from clinical-stage oncology company Akamis, received Fast Track designation from the FDA for the treatment of locally advanced rectal cancer (LARC) with proficient mismatch repair (pMMR) [1] - XuanZhu Bio holds exclusive rights for the development, production, and commercialization of NG-350A in the Greater China region [1] Group 2 - From October 30 to November 3, the National Healthcare Security Administration (NHSA) is conducting negotiations for the 2025 National Basic Medical Insurance Drug List, which includes price negotiations for innovative drugs [1] - XuanZhu Bio's drug Pyrocil has successfully passed the preliminary review for inclusion in the national medical insurance list, making its final inclusion critical for the company [1]